I85PREP
⌘ K
Egyptian Board Clinical Oncology study materials
Egyptian Board Clinical Oncology study resources

Egyptian Board Clinical Oncology: Thoracic Oncology (Lung, Pleura, Mediastinum)

Egyptian Board Clinical Oncology · Work through your exam, one topic at a time.

All guide sections

Thoracic Oncology (Lung, Pleura, Mediastinum)

What this domain tests

Thoracic items test stage-directed therapy in non-small cell lung cancer, biomarker-driven first-line selection, the locally advanced paradigm, small cell lung cancer paradigms, and the distinct biology of mesothelioma and thymic tumors.

Core rules

  • NSCLC staging (TNM 8th edition) drives treatment: stage I–II surgery with SBRT offered for medically inoperable early disease and as an option for small peripheral tumors; stage III is heterogeneous and generally chemoradiation followed by consolidation durvalumab (PACIFIC); stage IV is systemic.
  • Mandatory biomarker testing in advanced non-squamous NSCLC: EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK, KRAS G12C, plus PD-L1 expression. Test before treating.
  • Adjuvant targeted therapy: osimertinib for resected EGFR-mutant disease (ADAURA), alectinib for resected ALK-positive disease (ALINA); adjuvant atezolizumab or pembrolizumab for resected high-risk disease after chemotherapy.
  • First-line metastatic: pembrolizumab monotherapy when PD-L1 TPS ≥50%; platinum doublet plus pembrolizumab irrespective of PD-L1 when below that threshold (KEYNOTE-189/407).
  • SCLC: limited stage gets concurrent chemoradiation with cisplatin/etoposide, started early, followed by prophylactic cranial irradiation in selected responders; extensive stage gets platinum/etoposide plus atezolizumab or durvalumab.
  • Mesothelioma: platinum/pemetrexed with bevacizumab, or nivolumab plus ipilimumab in the first line; trimodality therapy in selected early epithelioid disease.

Worked example

A 52-year-old never-smoker with adenocarcinoma, symptomatic brain metastases and an EGFR exon 19 deletion. The correct first-line treatment is osimertinib, an irreversible third-generation EGFR TKI with CNS penetration (FLAURA). Cytotoxic chemotherapy and immunotherapy combinations are inferior here, and checkpoint inhibitors given with a TKI raise immune-toxicity risk.

Traps

  • Giving immunotherapy concurrently with an EGFR or ALK TKI - severe toxicity without benefit.
  • Reading PD-L1 as a rule-out test for all histologies; it is not used to withhold treatment in SCLC or mesothelioma.
  • Prescribing prophylactic cranial irradiation to all extensive-stage SCLC patients rather than the responder subset.
  • Missing that stage III disease is not treated with surgery by default, and that PACIFIC required no progression after chemoradiation.